BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Emerging functions for ANKHD1 in cancer-related signaling pathways and cellular processes

  • Received : 2020.04.24
  • Accepted : 2020.06.22
  • Published : 2020.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

ANKHD1 (ankyrin repeat and KH domain containing 1) is a large protein characterized by the presence of multiple ankyrin repeats and a K-homology domain. Ankyrin repeat domains consist of widely existing protein motifs in nature, they mediate protein-protein interactions and regulate fundamental biological processes, while the KH domain binds to RNA or ssDNA and is associated with transcriptional and translational regulation. In recent years, studies containing relevant information on ANKHD1 in cancer biology and its clinical relevance, as well as the increasing complexity of signaling networks in which this protein acts, have been reported. Among the signaling pathways of interest in oncology regulated by ANKHD1 are Hippo signaling, JAK/STAT, and STMN1. The scope of the present review is to survey the current knowledge and highlight future perspectives for ANKHD1 in the malignant phenotype of cancer cells, exploring biological, functional, and clinical reports of this protein in cancer.

Keywords

References

  1. Smith RK, Carroll PM, Allard JD and Simon MA (2002) MASK, a large ankyrin repeat and KH domain-containing protein involved in Drosophila receptor tyrosine kinase signaling. Development 129, 71-82 https://doi.org/10.1242/dev.129.1.71
  2. Li J, Mahajan A and Tsai MD (2006) Ankyrin repeat: a unique motif mediating protein-protein interactions. Biochemistry 45, 15168-15178 https://doi.org/10.1021/bi062188q
  3. Islam Z, Nagampalli RSK, Fatima MT and Ashraf GM (2018) New paradigm in ankyrin repeats: Beyond proteinprotein interaction module. Int J Biol Macromol 109, 1164-1173 https://doi.org/10.1016/j.ijbiomac.2017.11.101
  4. Sedgwick SG and Smerdon SJ (1999) The ankyrin repeat: a diversity of interactions on a common structural framework. Trends Biochem Sci 24, 311-316 https://doi.org/10.1016/S0968-0004(99)01426-7
  5. Mosavi LK, Cammett TJ, Desrosiers DC and Peng ZY (2004) The ankyrin repeat as molecular architecture for protein recognition. Protein Sci 13, 1435-1448 https://doi.org/10.1110/ps.03554604
  6. Hollenbeck JJ, Danner DJ, Landgren RM, Rainbolt TK and Roberts DS (2012) Designed ankyrin repeat proteins as scaffolds for multivalent recognition. Biomacromolecules 13, 1996-2002 https://doi.org/10.1021/bm300455f
  7. Valverde R, Edwards L and Regan L (2008) Structure and function of KH domains. FEBS J 275, 2712-2726 https://doi.org/10.1111/j.1742-4658.2008.06411.x
  8. Nazarov IB, Bakhmet EI and Tomilin AN (2019) KHDomain poly(C)-binding proteins as versatile regulators of multiple biological processes. Biochemistry (Mosc) 84, 205-219 https://doi.org/10.1134/s0006297919030039
  9. Nicastro G, Taylor IA and Ramos A (2015) KH-RNA interactions: back in the groove. Curr Opin Struct Biol 30, 63-70 https://doi.org/10.1016/j.sbi.2015.01.002
  10. Fragiadaki M and Zeidler MP (2018) Ankyrin repeat and single KH domain 1 (ANKHD1) drives renal cancer cell proliferation via binding to and altering a subset of miRNAs. J Biol Chem 293, 9570-9579 https://doi.org/10.1074/jbc.RA117.000975
  11. Yang C, Zheng J, Liu X et al (2020) Role of ANKHD1/LINC00346/ZNF655 feedback loop in regulating the glioma angiogenesis via staufen1-mediated mRNA decay. Mol Ther Nucleic Acids 20, 866-878 https://doi.org/10.1016/j.omtn.2020.05.004
  12. Sidor C, Borreguero-Munoz N, Fletcher GC, Elbediwy A, Guillermin O and Thompson BJ (2019) Mask family proteins ANKHD1 and ANKRD17 regulate YAP nuclear import and stability. Elife 8, e48601 https://doi.org/10.7554/eLife.48601
  13. Miles MC, Janket ML, Wheeler ED et al (2005) Molecular and functional characterization of a novel splice variant of ANKHD1 that lacks the KH domain and its role in cell survival and apoptosis. FEBS J 272, 4091-4102 https://doi.org/10.1111/j.1742-4658.2005.04821.x
  14. Santos Duarte Ada S, Traina F, Favaro PM et al (2005) Characterisation of a new splice variant of MASK-BP3(ARF) and MASK human genes, and their expression patterns during haematopoietic cell differentiation. Gene 363, 113-122 https://doi.org/10.1016/j.gene.2005.08.002
  15. Traina F, Favaro PM, Medina Sde S et al (2006) ANKHD1, ankyrin repeat and KH domain containing 1, is overexpressed in acute leukemias and is associated with SHP2 in K562 cells. Biochim Biophys Acta 1762, 828-834 https://doi.org/10.1016/j.bbadis.2006.07.010
  16. Muller P, Kuttenkeuler D, Gesellchen V, Zeidler MP and Boutros M (2005) Identification of JAK/STAT signalling components by genome-wide RNA interference. Nature 436, 871-875 https://doi.org/10.1038/nature03869
  17. Fisher KH, Fragiadaki M, Pugazhendhi D et al (2018) A genome-wide RNAi screen identifies MASK as a positive regulator of cytokine receptor stability. J Cell Sci 131, jcs209551 https://doi.org/10.1242/jcs.209551
  18. Patera F, Hautbergue GM, Wilson P, Evans PC, Ong AC and Fragiadaki M (2020) Ankhd1 enhances polycystic kidney disease development via promoting proliferation and fibrosis, bioRxiv (https://doi.org/10.1101/2020.03.04.977017)
  19. Sidor CM, Brain R and Thompson BJ (2013) Mask proteins are cofactors of Yorkie/YAP in the Hippo pathway. Curr Biol 23, 223-228 https://doi.org/10.1016/j.cub.2012.11.061
  20. Sansores-Garcia L, Atkins M, Moya IM et al (2013) Mask is required for the activity of the Hippo pathway effector Yki/YAP. Curr Biol 23, 229-235 https://doi.org/10.1016/j.cub.2012.12.033
  21. Du Toit A (2013) Cell signalling: A new Hippo pathway component. Nat Rev Mol Cell Biol 14, 196 https://doi.org/10.1038/nrm3534
  22. Yu FX, Zhao B and Guan KL (2015) Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 163, 811-828 https://doi.org/10.1016/j.cell.2015.10.044
  23. Machado-Neto JA, Lazarini M, Favaro P et al (2014) ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells. Exp Cell Res 324, 137-145 https://doi.org/10.1016/j.yexcr.2014.04.004
  24. Yao P, Li Y, Shen W et al (2018) ANKHD1 silencing suppresses the proliferation, migration and invasion of CRC cells by inhibiting YAP1-induced activation of EMT. Am J Cancer Res 8, 2311-2324
  25. Liu X-F, Han Q, Rong X-Z et al (2020) ANKHD1 promotes proliferation and invasion of non-small-cell lung cancer cells via regulating YAP oncoprotein expression and inactivating the Hippo pathway. Int J Oncol 56, 1175-1185
  26. Machado-Neto JA, Lazarini M, Favaro P et al (2015) ANKHD1 silencing inhibits Stathmin 1 activity, cell proliferation and migration of leukemia cells. Biochim Biophys Acta 1853, 583-593 https://doi.org/10.1016/j.bbamcr.2014.12.012
  27. Machado-Neto JA, de Melo Campos P, Favaro P et al (2014) Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells. Leuk Res 38, 251-257 https://doi.org/10.1016/j.leukres.2013.11.013
  28. Machado-Neto JA, Saad ST and Traina F (2014) Stathmin 1 in normal and malignant hematopoiesis. BMB Rep 47, 660-665 https://doi.org/10.5483/BMBRep.2014.47.12.020
  29. Dhyani A, Duarte AS, Machado-Neto JA, Favaro P, Ortega MM and Olalla Saad ST (2012) ANKHD1 regulates cell cycle progression and proliferation in multiple myeloma cells. FEBS Lett 586, 4311-4318 https://doi.org/10.1016/j.febslet.2012.10.037
  30. Dhyani A, Machado-Neto JA, Favaro P and Saad ST (2015) ANKHD1 represses p21 (WAF1/CIP1) promoter and promotes multiple myeloma cell growth. Eur J Cancer 51, 252-259 https://doi.org/10.1016/j.ejca.2014.11.012
  31. Dhyani A, Favaro P and Saad STO (2020) ANKHD1 is an S phase protein required for histone synthesis and DNA repair in multiple myeloma cells. Blood Cells Mol Dis 84, 102460 https://doi.org/10.1016/j.bcmd.2020.102460
  32. Zhou Z, Jiang H, Tu K et al (2019) ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res 38, 18 https://doi.org/10.1186/s13046-018-1011-0
  33. Zhu M, Li X, Tian X and Wu C (2015) Mask loss-offunction rescues mitochondrial impairment and muscle degeneration of Drosophila pink1 and parkin mutants. Hum Mol Genet 24, 3272-3285 https://doi.org/10.1093/hmg/ddv081
  34. Kitamata M, Hanawa-Suetsugu K, Maruyama K and Suetsugu S (2019) Membrane-deformation ability of ANKHD1 is involved in the early endosome enlargement. iScience 17, 101-118 https://doi.org/10.1016/j.isci.2019.06.020
  35. Hou SC, Chan LW, Chou YC et al (2009) Ankrd17, an ubiquitously expressed ankyrin factor, is essential for the vascular integrity during embryogenesis. FEBS Lett 583, 2765-2771 https://doi.org/10.1016/j.febslet.2009.07.025